Trial Profile

A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Etoposide; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
Indications Adenocarcinoma; Advanced breast cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer; Ovarian cancer; Pancreatic ductal carcinoma; Peritoneal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions
Sponsors AstraZeneca

04 Dec 2019 Status changed from active, no longer recruiting to completed.
08 Feb 2019 Planned End Date changed from 28 Jun 2019 to 31 Mar 2020.
08 Feb 2019 Planned primary completion date changed from 28 Jun 2019 to 31 Mar 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com